Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma.

Rui MengXueke ZhangTing ZhouMengjie LuoYijin Qiu

Published in: Expert review of pharmacoeconomics & outcomes research (2022)

Donafenib appears to be a cost-effective strategy compared with lenvatinib for the first-line treatment of patients with unresectable or metastatic HCC in China.

Keyphrases

squamous cell carcinoma
locally advanced
small cell lung cancer
liver metastases
rectal cancer